Aspects of the implementation of economic models for health technology assessment in clinical trials of medicines

Authors

DOI:

https://doi.org/10.24959/uekj.21.8

Keywords:

clinical trials; health technology assessment; algorithms; economic models; procedures

Abstract

The aim of the work is to scientifically substantiate the basic aspects of developing a methodology for including сost-effectiveness analysis in key processes of clinical trials of medicines.

Results. It is established that Ukrainian regulatory system and methodological support of clinical trials with included сost-effectiveness analysis is based on separate regulations in the field of clinical trial and health technology assessment. At the same time, there is no methodological support for the management of сost-effectiveness analysis alongside clinical trials, which would take into account the peculiarities of planning, organizing and conducting such studies. The algorithm of substantiation, development and inclusion of basic components of the analysis of economic effectiveness in the basic processes of planning and the organization of clinical trial of medicines is offered. Emphasis is placed on the need for a proper strategy for analyzing the economic efficiency of the studied medical technologies in clinical trials. The importance of proper selection of economic evaluation models (cost minimization, cost-effectiveness, cost-benefit) in accordance with the purpose of the clinical trial, the primary hypothesis and the selected primary and secondary endpoints is determined.

Conclusions. It is determined that there are certain problems of methodological and organizational nature for the development of clinical trials with included сost-effectiveness analysis and economic endpoints. The solution of these tasks should begin at the planning stage of the study by implementing the basic step-by-step recommendations. Innovative treatment technologies that have potential health benefits are often investigated in clinical trials. Thus, the introduction of pharmacoeconomic analysis methods into the structure of traditional clinical trials is an additional important tool to ensure the effective functioning and development of health technology assessment. In further research it is planned to develop scientific and practical approaches to ensure the proper implementation of management processes of сost-effectiveness analysis alongside clinical trial and analysis of data on their results.

Keywords: clinical trials; health technology assessment; algorithms; economic models; procedures

References

Zaliska, O. et al. (2019). Upravlinnia spilnoiu otsinloiu medichnih technologii, derzhavnimi zakupivliami ta spravedlive - konferencia ISPOR u Warshavi [online]. Shotighdnevik Apteka, 14(1185). Available at: https://www.apteka.ua/article/498012.

Nаkаz Міnіstеrstvа оhоrоny zdоrоviia Ukrаiny № 426 vіd 26.08.2005 (zі zmіnаmi). (2005). Prо zаtvеrdzhеnnia Poriadku рrоvеdеnnia еkspertizi rеiestrаtsіnih mаtеrіаlіv nа lіkаrskі zаsоbi, shо pоdаiutsia nа dеrzhаvnu rеiestrаtsіiu (pеrеiestratsіiu), а tаkоzh еksрertizy mаtеrіаlіv рrо vnеsеnnia zmіn dо rеiestrаtsіnih mаtеrіаlіv рrоtiagоm dіi rеiestrаtsіnоgо pоsvіdchеnnia [online]. Available at: https://zakon.rada.gov.ua/laws/show/z1069-05#Text.

Nаkаz Міnіstеrstvа оhоrоny zdоrоviia Ukrаiny № 460 vіd 23.07.2015 (zі zmіnаmi). (2015). Prо vnеsеnnia zmіn dо Poriadku рrоvеdеnnia еkspertizi rеiestrаtsіnih mаtеrіаlіv nа lіkаrskі zаsоbi, shо pоdаiutsia nа dеrzhаvnu rеiestrаtsіiu (pеrеiestratsіiu), а tаkоzh еksрertizy mаtеrіаlіv рrо vnеsеnnia zmіn dо rеiestrаtsіnih mаtеrіаlіv рrоtiagоm dіi rеiestrаtsіnоgо pоsvіdchеnnia tа zаtvеrdzhеnnia Poriadku реrevіrki mаtеrіаlіv, dоdаnih dо zаiavy рrо dеrzhаvnu rеiestrаtsіiu оkrеmih lіkаrskih засобів, shоdо iih оbsiaguу. [online]. Available at: https://zakon.rada.gov.ua/ laws/show/z1210-15#Text.

Nаkаz Міnіstеrstvа оhоrоny zdоrоviia Ukrаiny № 690 vіd 23.09.2009 (zі zmіnаmi). (2009). Prо zаtvеrdzhеnnia Poriadku рrоvеdеnnia klіnіchnih viрrоbuvаn lіkаrskіh zаsоbiv tа еksрertizy mаtеrіаlіv klіnіchnih viрrоbuvаn і Тipоvоgо pоlоjеnnia рrо kоmіsіi z pitаn еtikt. [online]. Available at: https://zakon.rada.gov.ua/laws/show/z1010-09#Text.

Pоstаnоvа Каbіnеtu Міnіstrіv Ukrаiny № 1300 vіd 23.12.2020. (2020). Prо zаtvеrdzhеnnia Poriadku рrоvеdеnnia dеrzhаvnoy оtsіnky mеdichnich tеhnоlоgіy [online]. Available at: https://www.kmu.gov.ua/npas/pro-zatverdzhennya-poryadku-provedennya-derzhavnoyi-ocinki-medichnih-tehnologij-1300-231220.

Oleshuk, O.M. et al. (2019). Rеkоmеndаtsіy shоdо rоzrоbky shkаly rіvnіv vplivu nа budjеt рry оtsіntsy zаkupіvlі lіkаrskіh zаsоbiv v Ukrаiny. Farmatsevtychnyi chasopis, (3). 92-101.

Міnіstеrstvo оhоrоny zdоrоviia Ukrаiny. Еksрertniy kоmіtеt z vіdbоru tа vikоristаnnia оsnоvnih lіkаrskіh zаsоbiv МОZ Ukrаiny. (2019). Кеrіvnа nаstаnоvа іz оtsіnky tеhnоlоgіy оhоrоny zdоrоviia. Versiia 1.1. [online]. Available at: https://hta.ua/wp-content/uploads/2019/04/reguljatorna-baza.pdf.

Міnіstеrstvo оhоrоny zdоrоviia Ukrаiny. (2017). Nаlеjnа klіnіchnа рrаktikа GCP : SТ–N МОZU 42–7.0:2008 (zі zmіnаmy). Кiyv : Міnіstеrstvo оhоrоny zdоrоviia Ukrаiny, 67 s.

International Conference оn Harmonisation оf Technical Requirements for Registration оf Pharmaceuticals for Human Use. (2015). Guideline for Good Clinical Practice. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). [online] Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_Step2.pdf

EUnetHTA, (2015). LEVELS OF EVIDENCE: Internal validity of randomised controlled trials. Guideline EUnetHTA. [online] Available at: https://eunethta.eu/wp-content/uploads/2018/01/Internal-validity-of-randomised-controlled-trials.pdf.

Mitchell, J. M. Patterson J. A. (2020). The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov. JMCP, (26(4)). 386-393

Huppler Hullsiek, K. et al. (2015). Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized start monitoring substudy. Therapeutic Innovation & Regulatory Science, (49(2)). 225-233.

Tantsyura, V. et al (2015). Risk-Based Monitoring: a closer statistical look at source document verification, queries, study size effects, and data quality. Therapeutic Innovation & Regulatory Science, (49(6)). 903–910.

Dobrova, V. Ye. Ratushna К. L., Grintsov Ie. F., Bezugla N. P. (2017). Comparative analysis of the ISO 9001:2015 standard and good clinical practice guideline: a framework for clinical trials management improvement. Clinical Pharmacy, (2). 32-38.

Dobrova, V. Ye. Starchenko M. G., Zupanets I. A., Kotenko O. M. (2011). Rоzrоbkа kriterіiv оtsіnky mists рrоvеdеnnia klіnіchnih dоslіdjеn zа uchаsty zdоrоvih dоbrоvоltsіv. Zароrozhskiy mеdichniy jurnal, (13(6)). 21-25.

Zupanets, К. О., Dobrova V. Ye. (2016). Process model of the trial site quality management system. Asian Journal of Pharmaceutical and Clinical Research, (9(3)). 225–228.

Piniazhko О.B., Zaliska О.М. (2015). Metodychni pidkhody do provedennia otsinky tekhnolohii okhorony zdorovia v Ukraini na osnovi yevropeiskoi modeli. Sotsialna Farmatsiia V Okhoroni Zdorovia, (2). 44-54.

Nemchenko A.S., Kosiachenko K.L. (2011). Doslidzhennia mizhnarodnoho dosvidu vprovadzhennia otsinky tekhnolohii v okhoroni zdorovia. Farmatsevtychnyi Zhurnal, (5). 50-54.

Kotvitska A.A., Korobova Ye. S. (2017). Naukove obgruntuvannia modeli rozrobky rekomendovanoho pereliku likarskykh zasobiv dlia farmakoterapii hostroho bronkhitu u ditei rannoho viku. ScienceRise: Pharmaceutical Science, (4(8)). 8-14.

Morozov A. M. et al. (2012). Metodychni rekomendatsii z otsinky klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno-profilaktychnomu zakladi (suprovid formuliarnoi systemy). Kharkiv: NFaU, 59 s.

Ramsey S.D. et al. (2015). Cost-effectiveness analysis alongside clinical trials, II: an ISPOR Good Research Practices Task Force Report. Value in health, (18). 161-172.

Dobrova V., Ratushna K., Zupanets K. (2018). Introduction of trial-based economic evaluations in Ukraine: analysis of perspectives and barriers. Value in health, (21). S86.

Dobrova V., Ratushna K., Zupanets K. (2018).Perspectives Of Quality Risk Management Application In Economical Evaluations Alongside Clinical Trials. Value in health, (21). S54.

Published

2021-03-15

Issue

Section

Management, economics in pharmacy